Regeneron Pharmaceuticals, Inc.

REGN · Healthcare · · USD

661.25 USD

0.00 (-1.00%)

● Updated 2026-07-10 17:07 Saudi Time ↻ Refresh

Short-term Mid-term Long-term

Fahodi Score HOLD Mid-term (Position)

/ 100

Technical 50

Trend & RS 58

Momentum 40

Fundamental 78

Macro 71

Liquidity 38

Component	Score	Weight
Technical	50.0	20%
Trend & RS	57.7	30%
Momentum	39.7	15%
Fundamental	77.8	10%
Macro	71.2	20%
Liquidity	38.4	5%

Trade Setup

Entry	660.24
Stop Loss	626.98 (5.0%)
Target 1 (1:1)	693.50 (+5.0%)
Target 2 (2:1)	726.76 (+10.1%)

ATR(14)	16.63 (2.5%)
Risk per Share	33.26
Reward:Risk	2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor	Score	Z
Value	79.0	+1.16
Momentum	39.7	-0.41
Quality	72.0	+0.88
Composite	63.5

Quality Scores

Piotroski F-Score 7 /9 — Strong

✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓

1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover

Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

Metric	Stock	Sector	vs Peers
P/E Ratio	16.1	22.0	-27% below
P/B Ratio	2.1	4.0	Below
Dividend Yield	56.0%	1.5%	Above avg

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Intrinsic Value (DCF) Significantly Undervalued

Intrinsic Value

1016.02

Market Price

661.25

Upside

+53.7%

Margin of Safety	+34.9%
Stage 1 PV (5yr FCF)	22,518,463,694
Terminal Value PV	84,000,082,136
Total Enterprise Value	106,518,545,830

Assumptions

Base FCF	3,434,526,603
Growth Rate (5yr)	19.0%
Terminal Growth	2.5%
Discount Rate (WACC)	9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.8%

Recommended Size

37.57%

Full Kelly

18.78%

Half Kelly

5.0%

Max Cap (Moderate)

Kelly inputs derived from quant score 57/100. Estimated win rate 57%, avg win 8.4%, avg loss 3.9%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary BUY

Bullish Signals

Bearish Signals

57.4

RSI(14)

5.9443

MACD

Relative Strength (RS) WEAKENING

/ 99

RS Rating

✓ O'Neil PASS (≥80)

RS vs SPY	↓ FALLING (-24.9% vs SPY 3M)
RS vs Sector	UNDERPERFORMING (Healthcare)
RS New High	No (62d since high)
Sector Outperformance	-17.2% (3M)

RS Line — stock / SPY (90 bars)

← older newer →

RS vs SPY 50-day SMA of RS

WEAKENING: Losing momentum — the stock was performing well but is now falling behind the market.

Technical Indicators

Indicator	Value	Signal
Rsi	57.4	NEUTRAL
Macd	5.9443	BULLISH
Ma Cross	648.77 / 700.27	DEATH CROSS
Trend Short		ABOVE SMA50
Trend Long		BELOW SMA200
Bollinger		MIDDLE
Volume	0.06x	LOW

Key Levels

Level	Price
52-Week High	821.11
Bollinger Upper	675.47
SMA(200)	700.27
SMA(50)	648.77
SMA(20)	631.48
Current Price	661.25
Bollinger Lower	587.49
52-Week Low	541.00
ATR(14)	16.63

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKDOWN Confidence

100%

Acc: 0.0 | Dist: 0.0 | Markup: 0.0 | Markdown: 2.0

Volume Spread Analysis (last 5 bars)

Date	Signal	Vol	Description
2026-07-06	Normal	0.72x	Normal bar — no special VSA pattern
2026-07-07	Normal	0.92x	Normal bar — no special VSA pattern
2026-07-08	Normal	0.75x	Normal bar — no special VSA pattern
2026-07-09	Normal	0.67x	Normal bar — no special VSA pattern
2026-07-10	Normal	0.06x	Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

Line	Value	Status
Tenkan-sen (9)	650.11	Above Kijun
Kijun-sen (26)	636.41	Base line
Senkou A	643.26	Leading span A
Senkou B	673.40	Leading span B
Cloud	643.26 – 673.40	Bearish (Red)
Price vs Cloud	660.24	Inside Cloud
Chikou Span	618.95	Bullish
Alignment Score	2/4	NEUTRAL